Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The underlying goal of this study is to assess [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Assess [18F] PBR06 and PET imaging | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| [18F] PBR06 | Drug | Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]PBR06, followed by PET imaging. |
|
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of AD, PD and MS research participants. | 1 year |
Not provided
Not provided
Inclusion Criteria:
The following criteria will be met for inclusion of AD subjects in this study:
The following criteria will be met for inclusion of PD subjects in this study:
The following criteria will be met for inclusion of MS subjects in this study:
The following criteria will be met for inclusion of healthy control subjects in this study:
Exclusion Criteria:
Alzheimer's subjects will be excluded from participation for the following reasons:
Parkinson's subjects will be excluded from participation for the following reasons:
MS subjects will be excluded from participation for the following reasons:
Healthy control subjects will be excluded from participation for the following reasons:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Danna Jennings, MD | Institute for Neurodegenerative Disorders | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute for Neurodegenerative Disorders | New Haven | Connecticut | 06510 | United States |
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D010300 | Parkinson Disease |
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C538798 | N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |